Megan Gibbs - Concepedia

Author

Megan Gibbs

Pfizer (United States)ORCID

Also Known As

M A Gibbs, M GIBBS, M Gibbs, M. Gibbs, Megan A Gibbs, Megan A. Gibbs, Megan Gibbs, Nicholas Ho

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Amgen (United States)AstraZeneca (United States)University of Washington AstraZeneca (Poland)

About

Megan Gibbs is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	387
2	Social Sciences	2	2	56
3	Engineering	1	1	11
4	Health Sciences	1	1	42
5	Biochemistry	1	1	10

Megan Gibbs

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL Angela C. Doran, R. Scott Obach, Bill J. Smith, Drug Metabolism and Disposition	2004	440
Inhibition of Cytochrome P-450 3A (CYP3A) in Human Intestinal and Liver Microsomes: Comparison of Ki Values and Impact of CYP3A5 Expression Megan Gibbs, Kenneth E. Thummel, Danny D. Shen, Drug Metabolism and Disposition	1999	244
Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies Jennifer Dong, David H. Salinger, Christopher J. Endres, Clinical Pharmacokinetics Translational MedicineMedicineBiostatisticsQuantitative PredictionPharmacology	2011	153
Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers Hélène M. Faessel, Bill J. Smith, Megan Gibbs, The Journal of Clinical Pharmacology	2006	104
Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers Hélène M. Faessel, Megan Gibbs, David J. Clark, The Journal of Clinical Pharmacology Dose LevelTobacco ControlHealthy Adult SmokersAddictionDrug Discovery	2006	93
Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors Thanh Huu Tran, Lisa L. von Moltke, Karthik Venkatakrishnan, Drug Metabolism and Disposition	2002	82
Effect of Inhibitor Depletion on Inhibitory Potency: Tight Binding Inhibition of CYP3A by Clotrimazole Megan Gibbs, Kent L. Kunze, William N. Howald, Drug Metabolism and Disposition	1999	55
Plasma Glucose and the Action of Calorie Restriction on Aging Roger McCarter, William Mejía, Yuji Ikeno, The Journals of Gerontology Series A NutritionAgingAnti-agingBiogerontologyCaloric Restriction	2007	42
Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor John P. Gibbs, Maurice G. Emery, Ian McCaffery, The Journal of Clinical Pharmacology	2010	39
Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) John P. Gibbs, Sameer Doshi, Mita Kuchimanchi, The Journal of Clinical Pharmacology	2016	39

Page 1